Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 417 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sterile saline injection Clear all

Conditions: Sickle Cell Anemia
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 10 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 7 more

Conditions: Healthy
Interventions: CD388 Injection, Saline placebo; Combination Product · Drug
Lead sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 65 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Malignant Pleural Mesothelioma, Solid Tumors
Interventions: pemetrexed, cisplatin and CBP501, pemetrexed and cisplatin, pemetrexed, cisplatin and CBP501, dose finding; Drug
Lead sponsor: CanBas Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Scottsdale, Arizona • Tucson, Arizona • Duarte, California + 9 more

Conditions: Plasmodium Falciparum Malaria
Interventions: AMA1-C1/Alhydrogel®, CPG 7909 Oligodeoxynucleotide (VaxImmune®); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, New York

Conditions: ASCVD, Elevated Cholesterol
Interventions: Inclisiran Sodium, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 145
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more

Conditions: Obesity
Interventions: Exenatide, Normal saline .2cc subcutaneous injection; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Risk Reduction
Interventions: Trivalent Salmonella Conjugate Vaccine (TSCV) Full-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Half-Strength Formulation, Trivalent Salmonella Conjugate Vaccine (TSCV) Dilutional Half-Strength Formulation, Placebo; Biological · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 49 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stiff Knee Gait, Brain Injuries
Interventions: placebo, botulinum toxin A (BTX-A); Drug
Lead sponsor: Mary Free Bed Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Critical Limb Ischemia
Interventions: Cord blood stem cell injection; Biological
Lead sponsor: Richard Burt, MD; Other
Eligibility: 18 Years to 72 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Beta Haemolytic Streptococcal Infection
Interventions: GBS III-TT, Tetanus and diptheria toxoids vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 667 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 3
States / cities: Augusta, Georgia • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: Pain, Postpartum Depression
Interventions: Epidural saline + IV saline, Epidural morphine 3 mg + IV saline, Epidural morphine 3 mg + IV ketamine 0.3 mg/kg; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions: Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control); Biological · Other
Lead sponsor: Restem, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Miami, Florida • Sioux Falls, South Dakota

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Upper Limb Spasticity
Interventions: DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 26
States / cities: Downey, California • Fountain Valley, California • Long Beach, California + 22 more

Conditions: Postoperative Pain
Interventions: Placebo, Drug .5% Ropivacaine, 20 cc of 0.25% ropivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Delirium, Sleep
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions: Azficel-T (autologous fibroblasts), Placebo; Biological · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Los Angeles, California • Stanford, California • New York, New York

Conditions: Coronavirus Disease 2019
Interventions: Placebo, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palm Springs, California • Rancho Mirage, California + 9 more

Conditions: Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions: MET097 Injection, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 29
States / cities: Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: Alemtuzumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Baker's Cyst
Interventions: Platelets-Rich-Plasma, Corticosteroid; Other · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Placebo, Trivalent Inactivated Influenza; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 21 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions: Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection; Drug
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Multiple Sclerosis
Interventions: Tysabri; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

A Phase II Trial of Regadenoson in Sickle Cell Anemia

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

AMA1-C1/Alhydrogel + CpG 7909 for Malaria

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women

Salmonella Conjugates CVD 2000: Study of Responses to Vaccination With Trivalent Salmonella Conjugate Vaccine to Prevent Invasive Salmonella Disease

Efficacy of Botulinum Toxin Injections in the Rectus Femoris to Treat Stiff Knee Gait Following Acquired Brain Injury

Efficacy and Safety of Umbilical Cord Blood Injection for Critical Limb Ischemia

Prevention of GBS Colonization Via Immunity

Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy

Investigation of Sleep in the Intensive Care Unit

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation

PRP vs Corticosteroid in Baker's Cyst

Th1 Response to Influenza: Aging and Vaccine Efficacy

Sublingual vs IV Atropine Bioavailability Study

Effect of Tysabri in Patients With Relapsing-Remitting Multiple Sclerosis: A Follow-up Magnetization Transfer Imaging (MTI) Study